Year None2022202120202019201820172016 02-24-2022 Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis 02-24-2022 Pliant Therapeutics to Participate in Upcoming Investor Conferences 01-11-2022 Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3
